Immunology

CRISPR gene editing
#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #PCR #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs

CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs By Dr John Comley It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions or modifications to… Read More

#Archive

Gene therapy
#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Regenerative Medicine #Regulatory #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Cell Therapy & Gene Therapy – The emerging fourth pillar of healthcare systems

Cell Therapy & Gene Therapy - The emerging fourth pillar of healthcare systems By Keith Thompson As the CEO of an organisation that deals exclusively in cell therapy and gene therapy, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine… Read More

#Archive

Molecules
#Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #High Content Screening #Immunology #Lead discovery #Oncology #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Therapeutics #Toxicology

Fusion therapy – A new approach to combining treatments

By Dr Thomas Mehrling Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for new ways to enhance treatment effect and tolerability. New fusion technology molecules appear to offer a beneficial synergy, but will this withstand… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #PCR #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry

Ion Channels – Increasingly Enticing Targets For Drug Discovery

Ion Channels - Increasingly Enticing Targets For Drug Discovery by Dr Douglas Krafte and Deborah Erickson Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease. Pfizer Inc’s… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Microbiome #Molecular medicine #Oncology #Patent Law #PCR #Pharmacogenomics #Pharmacokinetics / Pharmacodynamics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Reigniting Pharmaceutical Innovation Through Holistic Drug Targeting

By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microbiology #Microbiome #Molecular medicine #Oncology #Pathology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Metabolomics – A Playbook for Functional Genomics

Metabolomics - A Playbook for Functional Genomics By Dr David Ferrick If we have learned anything from scientific research in the last 20 years, it is that finding cures to complex diseases is difficult. Despite the promise of the genomic revolution, disease progression and patient outcomes are still not easily… Read More

#Archive

High content screening
#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Latest Developments in High Content Screening Systems

By Dr John Comley High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, high content imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Oncology #Preclinical #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Ex Vivo vs In Vivo – The challenge of generating meaningful results with traditional cell culture

By Dr James Lim and Dr Fred Aswad While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results. This article discusses current attempts to make results from cell culture systems more biologically relevant which,… Read More

#Archive

Stem cells
#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biobanking #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

The stem cell dilemma: Reprogramming in-house versus off-the-shelf

  by Dr John Comley The case for using more physiologically-relevant cells for modelling disease pathophysiology, for understanding a drug’s mechanism of action, in toxicology/safety testing and in phenotypic drug screening assays is now well accepted. Human induced pluripotent stem cells (iPSCs) are seen as a resource from which to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Role Of Immunodeficient Animal Models In Advancing Immuno-Oncology Research

The Role Of Immunodeficient Animal Models In Advancing Immuno-Oncology Research By Dr Michael Seiler From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer. Among those, spontaneous and genetically engineered immunodeficient strains can be administered in… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Biomarkers #Cell therapy #Clinical specialities #Clinical trials #Drug development #Gene therapy #High Content Screening #High throughput screening #Imaging #Immunology #Molecular medicine #Oncology #Precision medicine #Preclinical #Regulatory #RNA #Stem cells #Therapeutics

Magnetic Resonance Imaging (MRI) In Drug Development

Magnetic Resonance Imaging (MRI) In Drug Development By Dr Geoff J.M. Parker Magnetic Resonance Imaging (MRI) can be used to provide quantitative measurements in the form of imaging biomarkers. These measurements have a number of attractive characteristics: They are non-invasive, can provide organ and lesion localisation of morphology, physiology and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Molecular medicine #Orphan drugs #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Therapeutics #Translational #Translational chemistry

Drug Discovery in a Multi-Omics World

Drug Discovery in a Multi-Omics World By Mike Furness Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug development. This… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype

Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann While Chimeric Antigen Receptor T-cells (CAR-T), have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Regulatory #RNA #Stem cells #Therapeutics

Using Syngeneic Models for the Discovery of Combination Therapy Targets & Predictive Biomarkers of Immunotherapy Efficacy

By Dr Jean- Pierre Wery Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initially designed to kill rapidly dividing cells. These traditional treatments, namely chemotherapy and radiotherapy, remain… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Phenotypic Drug Discovery: Striving towards high level biological relevance

Phenotypic Drug Discovery: Striving towards the highest level of biological relevance By Dr John Comley Phenotypic drug discovery (PDD) implies screening where the molecular mechanism of action is not assumed and does not require knowledge of the molecular target. As such phenotypic drug discovery is comparable to empirical screening, which… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #In Silico Biology #Lead discovery #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics

How Neutron Science Has Enabled Innovation in Drug Design and Delivery

How Neutron Science Has Enabled Innovation in Drug Design and Delivery By Dr Giovanna Fragneto Meeting global health challenges, from cancer to viral infections, requires a profound understanding of living processes – not just at the level of cells but right down at the molecular level. And designing the most… Read More

#Archive